MedPath

Chronic Endometritis and Recurrent Miscarriage - The CERM trial

Phase 1
Conditions
Chronic Endometritis and Recurrent Miscarriage
Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
Registration Number
EUCTR2019-000585-38-GB
Lead Sponsor
niversity Hospitals Coventry and Warwickshire NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
Female
Target Recruitment
3062
Inclusion Criteria

Inclusion criteria - screening
•Age =18 to <42
•Two or more consecutive first trimester intrauterine miscarriages (=14 weeks gestation).
•Women who agree to use barrier methods of contraception during the following cycles: biopsy preparation, screening-biopsy, waiting for the results and during the intervention.

Inclusion criteria - RCT
•Women with =5 CD138+ cells/10mm2.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1500
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

Exclusion criteria – screening
•Treatable cause(s) of RM for example:
oantiphospholipid antibody syndrome
othyroid disease
oparental karyotypical abnormalities.
•Known sub-septate uterus.
•Poorly controlled diabetes (HbA1c >48mmol/mol)
•Allergy to doxycycline or its excipients.
•Doxycycline contraindicated
•Antibiotics in the current menstrual cycle
•Taking a medication that may interact with doxycycline
•Myasthenia Gravis.
•Systemic lupus erythematosus (SLE).
•Immunodeficiency disorder.
•Alcohol dependency*
•Long-term antibiotic(s) use.
•Menstrual cycle =21 - =42 days.
•Unable to give informed consent.
•Participation in another clinical trial of an investigational medicinal product (CTIMP) within the last 90 days.
•Women who are breast feeding.
•Pregnancy

Exclusion criteria – RCT
•A course of antibiotics between screening registration and randomisation to RCT**
•A delay of longer than three months between biopsy result and randomisation to RCT**
•Known serious liver disease*1
•Taking a medication that may interact with doxycycline
•Any co-morbid disease or condition that would make the patient unsuitable for the trial*1
•Pregnancy

*As judged by a medically qualified doctor assessing trial eligibility informed by referral letter from GP and hospital records

**If a woman has a course of antibiotics between screening registration and randomisation or was registered for screening over three months before randomisation to the RCT they will not be eligible for trial randomisation at the time. These women should be given the option to re-screen and have another biopsy to confirm eligibility for randomisation.

1If a clinician has doubts about a participants’ suitability for the trial because of a long-term medical condition they should undertake a Full Blood Count (FBC) and Liver function tests (LFTs); in order for a woman to be included in the trial the following should apply:
•WBC >3x10^9/L,
•Neutrophils >1.5x10^9/L,
•Platelets >75x10^9/L, Hb>100g/L
•Bilirubin <1.5XULN*
•AST/ALT <3xULN*
•Albumin >30g/dL).
* ULN = Upper Limit of Normal
All required additional checks must be documented in the patients’ medical notes

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath